Table 2 Assessment of visual analogue pain scale score between groups.

Assessment of visual analogue pain scale score (% reduction)

 EnMax

6.90 ± 0.75

[6.673–7.127]

2.09 ± 1.42

[1.661–2.519]

(69.65%)

< 0.001

1.14 ± 1.02

[0.832–1.448]

(83.44%)

< 0.001

0.47 ± 0.63

[0.279–0.661]

(93.10%)

< 0.001

 Comparator

6.83 ± 0.82

[6.582–7.078]

2.71 ± 1.71

[2.193–3.227]

(60.26%)

< 0.001

1.42 ± 1.62

[0.930–1.910]

(79.09%)

< 0.001

1.07 ± 0.94

[0.786–1.354]

(84.32%)

< 0.001

 ^*P Value

0.730

0.022

-

0.387

-

0.003

-

 Placebo

6.52 ± 1.07

[6.062–6.978]

4.52 ± 1.56

[3.853–5.187]

(30.65%)

< 0.001

3.71 ± 2.34

[2.709–4.711]

(43.06%)

< 0.001

2.23 ± 1.89

[1.422–3.038]

(65.69%)

< 0.001

 ^#P Value

0.162

< 0.001

-

< 0.001

-

< 0.001

-

Assessment of inflammation using VRS score (% reduction)

 EnMax

2.09 ± 0.53

[1.930–2.250]

0.97 ± 0.78

[0.734–1.206]

(53.40%)

< 0.001

0.57 ± 0.66

[0.370–0.770]

(72.72%)

< 0.001

0.21 ± 0.41

[0.0860–0.334]

(89.77%)

< 0.001

 Comparator

2.11 ± 0.73

[1.970–2.250]

0.85 ± 0.68

[0.644–1.056]

(59.55%)

< 0.001

0.71 ± 0.63

[0.519–0.901]

(66.29%)

< 0.001

0.40 ± 0.49

[0.252–0.548]

(80.89%)

< 0.001

 ^*P Value

0.739

0.407

-

0.771

-

0.382

-

 Placebo

2.28 ± 0.71

[1.976–2.584]

1.33 ± 0.73

[1.018–1.642]

(41.66%)

0.001

1.14 ± 0.57

[0.896–1.384]

(50.00%)

< 0.001

0.81 ± 0.51

[0.592–1.028]

(64.58%)

< 0.001

 ^#P Value

0.188

0.534

-

0.059

-

0.074

-